3 results
Primary ObjectiveThe primary objective of this double-blind, randomized, placebo-controlled, Phase 3 study is to assess the efficacy and safety of treatment with Kiacta in adult patients with AA amyloidosis. Efficacy will be assessed by the time…
Primary end points:Safety (>1 toxic death per arm) and tolerability (relevant grade 4 toxicities) in not more than 33% of patients for the three treatment arms.Secondary end points:* Reduction of grade 2-4 key side effects in the experimental…
Primary Objective: To confirm that the lithium headcoil is capable of measuring lithium signals related to clinical doses in the brains of BD patients (MDR, art 82), and then to establish the correlation of neuroimaging data of lithium…